argenx SE (NASDAQ:ARGX) Stake Lifted by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. increased its position in argenx SE (NASDAQ:ARGX) by 3.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,524 shares of the company’s stock after purchasing an additional 440 shares during the quarter. argenx makes up about 1.2% of EFG Asset Management North America Corp.’s investment portfolio, making the stock its 10th largest holding. EFG Asset Management North America Corp.’s holdings in argenx were worth $8,942,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Whipplewood Advisors LLC purchased a new position in argenx during the fourth quarter valued at $37,000. Global Retirement Partners LLC increased its stake in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after acquiring an additional 48 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after acquiring an additional 61 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in argenx by 78.6% during the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock worth $46,000 after acquiring an additional 33 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after purchasing an additional 21 shares during the period. 60.32% of the stock is currently owned by institutional investors.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $607.95 on Tuesday. The stock’s 50-day simple moving average is $633.44 and its two-hundred day simple moving average is $600.67. The stock has a market capitalization of $36.94 billion, a price-to-earnings ratio of -690.85 and a beta of 0.59. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. As a group, equities analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ARGX shares. Citigroup reissued an “outperform” rating on shares of argenx in a research report on Friday, February 28th. HC Wainwright boosted their target price on argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Oppenheimer raised their price target on argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a report on Friday, February 28th. JMP Securities upped their price target on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. Finally, Guggenheim increased their price objective on shares of argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.